{"filings":[{"id":1303920,"accession_number":"0001493152-26-030286","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2026-06-26T20:05:40+00:00","items":["7.01","9.01"],"status":"ready","headline":"BriaPro subsidiary reports 9-month net loss of $712K; going concern uncertainty","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss for 9 months ended April 30, 2026: $712,236, vs $519,804 in prior-year period.","Accumulated deficit of $1,892,661; cash $299,950 vs $1 at July 31, 2025.","Acquired sCD80 license from parent BriaCell for 23,972,589 shares valued at $846,532.","Due to related parties (BriaCell) $2,093,345; going concern depends on parent financing.","R&D expenses $649,991; granted 7,189,000 RSUs to directors on April 1, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":814916,"accession_number":"0001493152-26-026953","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2026-06-03T01:32:29+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"BriaCell closes $4.7M best-efforts equity offering; 1.45M shares at $3.25 each","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$4.7M from sale of 1,449,300 common shares at $3.25/share in a best-efforts offering.","Placement agent ThinkEquity receives 7.5% cash fee and 5-year warrants for 72,465 shares at $4.0625.","Net proceeds to be used for working capital, general corporate purposes, and business advancement.","Offering closed June 2, 2026; shares issued under effective shelf registration statement (Form S-3)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106189,"accession_number":"0001493152-26-014156","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BriaPro subsidiary reports $472K net loss for six months; going concern risk","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BriaPro net loss widened to $472,231 for six months ended Jan 31, 2026 vs $233,185 a year ago.","Accumulated deficit $1.65M; negative working capital $1.64M; cash only $1.","Going concern: dependent on parent BriaCell for financing; material uncertainty noted.","On Feb 18, 2026, BriaPro agreed to acquire sCD80 license from BriaCell for cancer therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106188,"accession_number":"0001493152-26-009382","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BriaCell shareholders ratify auditor, elect six directors, approve equity plan at AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["MNP LLP ratified as auditor with 3,431,761 for, 70,934 against.","Six directors elected: Gross, Bondarenko, Williams, Taub, Embro-Pantalony, Schmieg. For votes ranged from ~1.837M to ~1.848M.","Omnibus equity incentive plan re-approved: 1,524,081 for, 362,949 against (51% of shares voted)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106187,"accession_number":"0001493152-26-007587","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BriaCell transfers exclusive sCD80 license to BriaPro; receives 23.97M shares, increases stake to 78%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BriaCell transfers exclusive license for Soluble CD80 to BriaPro for 23,972,589 BriaPro shares, increasing stake to ~78%.","BriaCell provides up to $3M credit facility to BriaPro for R&D; each drawdown subject to BriaCell approval.","Transaction expected to close March 12, 2026, subject to disinterested shareholder approval and independent valuation.","License originally from University of Maryland Baltimore County; sCD80 showed anti-tumor activity in animal models.","BriaPro stock valued at approx. C$1.18M aggregate; BriaPro to pay 2% royalties to UMBC upon commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106186,"accession_number":"0001493152-26-002430","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"BriaCell closes $30M public offering of units; warrants trade under BCTXL","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed public offering of 5,366,726 units at $5.59/unit for gross proceeds of ~$30M.","Each unit comprises one common share (or pre-funded warrant) and one warrant at $6.93.","Warrants started trading on Nasdaq on Jan 14 under symbol BCTXL; expire in 5 years.","Net proceeds to fund working capital, general corporate purposes, and business advancement.","Placement agent warrants issued to ThinkEquity for 161,001 shares at $8.385 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122467,"accession_number":"0001493152-25-029363","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BriaPro subsidiary posts Q1 operating loss $258K, R&D spend jumps 5x, going concern doubt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $244,738 for three months ended Oct 31, 2025, vs $82,123 prior year; operating loss $258,445.","R&D expenses surged to $237,501 from $48,500, driven by wages $161,875 and supplies $75,626.","Cash remains $1; total assets $180,708; current liabilities $1,403,120 (including $1.31M due to parent BriaCell).","Shareholders' deficit $1,390,648; accumulated deficit $1,425,163; going concern uncertainty noted as dependent on BriaCell funding.","No auditor review performed; warrants liability $168,236 with Black-Scholes valuation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122466,"accession_number":"0001493152-25-025469","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BriaPro subsidiary reports $740K loss; going concern doubt flagged by auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BriaPro net loss $740,216 for year ended July 31, 2025, accumulated deficit $1,180,425.","Auditor's report includes material uncertainty about BriaPro's ability to continue as a going concern.","BriaPro has $1 cash, $1.15M current liabilities, and total assets of $184,526 primarily intangible assets.","Subsidiary wholly dependent on BriaCell for financing; no commercial operations yet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139162,"accession_number":"0001641172-25-025438","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2025-08-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BriaCell Therapeutics announces 1-for-10 reverse stock split effective August 25, 2025 to maintain Nasdaq listing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Share consolidation of 1 post-split share for every 10 pre-split shares, effective August 25, 2025.","Post-consolidation common shares trade on Nasdaq (BCTX) and TSX (BCT) under same symbols.","Consolidation intended to ensure continued compliance with Nasdaq listing requirements.","No fractional shares issued; fractions less than 0.5 cancelled, 0.5 or greater rounded up to one share.","Outstanding convertible securities' exercise/conversion prices proportionately adjusted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139161,"accession_number":"0001641172-25-019892","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"BriaCell closes $15M public offering of 12M units at $1.25/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $15M before fees; 12,000,000 units sold at $1.25 per unit.","Each unit comprises one common share (or pre-funded warrant at $0.001) and one warrant exercisable at $1.50 for five years.","ThinkEquity acted as sole placement agent; cash fee of 7.5% of gross proceeds.","Net proceeds earmarked for working capital, general corporate purposes, and advancement of business objectives.","Relies on TSX exemption for interlisted issuers; no Canadian prospectus filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156709,"accession_number":"0001641172-25-015516","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BriaPro Therapeutics (2/3 owned by BriaCell) reports net loss of $519,804 for 9 months, cash only $1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $519,804 for nine months ended April 30, 2025 vs. $316,517 in prior year period.","Accumulated deficit $960,013; cash and cash equivalents $1.","Due to related parties (BriaCell group) $937,432, up from $424,654 at July 31, 2024.","Warrant liability revalued to $176,409 from $149,841; change in fair value gain of $26,568.","Going concern uncertainty: company has not commenced commercial operations and expects further losses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156708,"accession_number":"0001641172-25-006428","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"BriaCell closes $13.8M public offering of units with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$13.8M from 3,066,666 units at $4.50/unit, including 399,999 from over-allotment","Each unit consists of one common share (or pre-funded warrant) and one warrant exercisable at $5.25 for five years","Warrants commenced trading on Nasdaq under BCTXZ on April 25, 2025","Net proceeds to be used for working capital, general corporate purposes, and advancing business objectives","ThinkEquity acted as sole book-running manager; offering closed on April 28, 2025"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175125,"accession_number":"0001493152-25-010035","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BriaPro Therapeutics (2/3 owned by BriaCell) reports six-month net loss of $233K, cash only $1, going concern warning","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for six months ended Jan 31, 2025: $233,185; accumulated deficit $673,394.","Cash and cash equivalents only $1; total assets $192,161 mostly intangible patents.","Current liabilities $658,049 due to related party (BriaCell); warrant liability $172,991.","No revenue; R&D expenses $130,023, G&A $80,012 for six months.","Going concern warning: material uncertainty about ability to raise capital to continue operations."],"consensus_eps_estimate":-17.776,"consensus_eps_actual":-5.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175124,"accession_number":"0001493152-25-006419","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BriaCell regains Nasdaq minimum bid price compliance; delisting risk resolved","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice of compliance with $1.00 minimum bid price requirement on Feb 12, 2025.","Deficiency letter previously received on August 22, 2024; now resolved.","Matter is closed; company continues listing on Nasdaq Capital Market.","Common shares (BCTX) and warrants (BCTXW) remain eligible for trading."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175123,"accession_number":"0001493152-25-005204","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BriaCell shareholders ratify MNP LLP as auditor and elect six directors at AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders ratified MNP LLP as auditor with 11,973,291 votes for, 1,361,710 withheld.","All six director nominees elected; Dr. Williams received 5,955,745 votes for.","Total shares voted: 13,335,031 out of 36,779,061 issued and outstanding (pre-reverse split)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175122,"accession_number":"0001493152-25-005043","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"BriaCell raises $3.05M in public offering of 762,500 common shares at $4.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed best-efforts offering of 762,500 common shares at $4.00/share on Feb 5, 2025; gross proceeds $3.05M.","Net proceeds to be used for working capital, general corporate purposes, and advancement of business objectives.","ThinkEquity acted as sole placement agent; received 7.5% cash fee and warrants to purchase 38,125 shares at $5.00/share (5-year term).","Offering conducted under effective shelf registration S-3; TSX exemption relied upon for listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175121,"accession_number":"0001493152-25-003977","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BriaCell completes 15:1 share consolidation to comply with Nasdaq listing","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Consolidation effective Jan 24, 2025; post-consolidation shares begin trading Jan 29, 2025.","Shares reduced from 44,204,061 to 2,946,940; no fractional shares issued.","New CUSIP: 107930208; tickers BCTX and BCTXW unchanged on Nasdaq and TSX.","Exercise prices and conversion ratios on convertible securities proportionately adjusted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175120,"accession_number":"0001493152-25-000282","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BriaCell announces 1-for-15 share consolidation to maintain Nasdaq listing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Consolidation ratio: 1 post-consolidation share for every 15 pre-consolidation shares.","Effective date expected January 24, 2025; trading on TSX and Nasdaq from Jan 29, 2025.","No fractional shares issued; fractions cancelled for no consideration.","Convertible securities exercise prices and share counts proportionally adjusted.","Action needed to comply with Nasdaq Capital Market listing requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175119,"accession_number":"0001493152-25-000281","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BriaCell postpones AGM to Feb 5, 2025 due to Canada Post disruption","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AGM rescheduled from Jan 23 to Feb 5, 2025 at 9:00 a.m. ET in Toronto.","Record date of Dec 9, 2024 unchanged; proxy deadline Feb 3, 2025.","Postponement due to Canada Post mail disruption for extra proxy solicitation time.","ISS recommends shareholders vote FOR management proposals per proxy statement.","Votes already cast remain valid; shareholders urged to vote if not yet done."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192066,"accession_number":"0001493152-24-050212","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BriaPro reports Q1 net loss of $82K; cash at $1; going concern uncertainty","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $82,123 for three months to Oct 2024 vs $128,026 loss in prior year period.","Total assets $195,979; intangible assets (patents) net $195,978.","Current liabilities $522,835; shareholders' deficit $487,817; cash unchanged at $1.","Due to BriaCell (related party) $503,709; no revenue or commercial operations.","Going concern doubt due to pre-clinical stage and need for additional financing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192065,"accession_number":"0001493152-24-049999","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"BriaCell closes $5.55M public offering of 7.4M units at $0.75/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwritten public offering of 7,400,000 units closed Dec 13, 2024; gross proceeds $5.55M.","Each unit: 1 common share + 1 warrant exercisable at $0.9375 for 5 years.","Underwriter ThinkEquity received 370,000 representative's warrants on same terms.","Net proceeds to be used for working capital, general corporate purposes, and business advancement.","Offering made under effective shelf registration statement (S-3 No. 333-276650)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192064,"accession_number":"0001493152-24-047606","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Marc Lustig resigns from BriaCell Therapeutics board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Marc Lustig resigned from the board of directors on November 23, 2024.","The company thanked Mr. Lustig for his contributions.","No replacement or further details were provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192063,"accession_number":"0001493152-24-043322","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BriaPro sub of BriaCell reports $420K net loss, going concern uncertainty","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BriaPro incurred net loss of $420,287 for year ended July 31, 2024; accumulated deficit $440,209 since incorporation in May 2023.","Total assets $199,797; current liabilities $455,650; shareholders' deficit $405,694; cash balance $1.","Auditor's report includes material uncertainty paragraph about going concern; company is pre-clinical with no commercial operations.","Intangible assets (patents) of $199,796 acquired from BriaCell via spinout arrangement on August 31, 2023.","BriaCell beneficially owns 2/3 of BriaPro's outstanding common shares (31,963,452 of 47,945,178 shares)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192062,"accession_number":"0001493152-24-039218","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2024-10-02T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"BriaCell closes $5M offering of 5.1M shares and warrants at $0.975/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["5,128,500 common shares and warrants to purchase 5,128,500 common shares sold at $0.975 per unit.","Gross proceeds ~$5M; warrants exercisable at $0.85/share for five years from issuance.","Proceeds for working capital, general corporate purposes, and business advancement.","ThinkEquity acted as sole placement agent; placement agent warrants issued.","Offering closed October 2, 2024, under effective shelf registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192061,"accession_number":"0001493152-24-039016","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BriaCell: 100% resolution of temporal lobe brain metastasis in heavily pre-treated breast cancer patient","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Patient with 'eye-bulging' orbital tumor and brain metastasis achieved complete resolution of temporal lobe lesion at 8 and 11 months on Bria-IMT plus checkpoint inhibitor.","Heavily pre-treated patient had failed 8 prior regimens including ADC therapy; continues treatment after 17 cycles and 12 months on study.","Orbital tumor showed near-complete resolution; tumor markers (blood tests) sustained drop confirming imaging results.","CEO cites unprecedented potential in metastatic breast cancer brain metastasis; Phase 3 study evaluating brain metastasis subgroup ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208557,"accession_number":"0001493152-24-036055","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"BriaCell closes $8.5M public offering of 12.3M shares at $0.69 each","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $8,504,250 from sale of 12,325,000 common shares at $0.69/share.","Placement agent ThinkEquity received 7.5% cash fee and 5-year warrants for 616,250 shares at $0.8625.","Net proceeds to be used for working capital, general corporate purposes, and advancing business objectives.","Offering closed on September 12, 2024; securities sold under effective shelf registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208556,"accession_number":"0001493152-24-035737","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BriaCell reports median OS of 15.6 months in Phase 2 Bria-IMT study; FDA path cleared for Bria-PROS+","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median overall survival of 15.6 months in 25 patients receiving Phase 3 Bria-IMT formulation vs 6.7–9.3 months in literature controls.","FDA Pre-IND meeting gave positive feedback; waived animal toxicology/PK studies for Bria-PROS+ prostate cancer trial.","No drug-related discontinuations reported in the Phase 2 study; ongoing Phase 3 pivotal study NCT06072612.","Poster presentation at SITC 2024 (Nov 8, Houston) on novel targeted immunotherapy candidates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208555,"accession_number":"0001493152-24-033753","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2024-08-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"BriaCell receives Nasdaq deficiency notice for bid price below $1.00; 180-day cure period until Feb 18, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency letter on Aug 22, 2024; bid price below $1.00 for 30 consecutive business days.","Has until Feb 18, 2025 to regain compliance via closing bid price of $1.00+ for 10 consecutive days.","May qualify for second 180-day cure period if it meets other listing standards and effects a reverse split.","TSX listing unaffected; common shares continue trading on Nasdaq under BCTX."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208554,"accession_number":"0001493152-24-028343","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BriaCell Quadruples PFS to 9.1 Months in Top Responder Metastatic Breast Cancer Patient","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PFS extended to 9.1 months in top responder patient, quadruple historical controls (1.7-2.3 months).","Patient had failed 8 prior regimens including ADC therapy; continues on BriaCell treatment.","Brain lesion undetectable, orbital lesion shrinking; tumor markers markedly decreased from pre-treatment.","Phase 2 study of Bria-IMT regimen plus immune checkpoint inhibitor in metastatic breast cancer.","Patient remains alive; company plans to replicate results in ongoing Phase 3 study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208553,"accession_number":"0001493152-24-026349","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2024-07-05T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"BriaCell receives Nasdaq notice for failing $35M minimum MVLS requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on July 3, 2024, for MVLS below $35M for 33 consecutive business days.","Has until December 30, 2024 (180-day compliance period) to regain compliance.","To regain compliance, MVLS must close at $35M+ for at least 10 consecutive business days.","Failure could lead to delisting, with appeal rights to a Nasdaq Hearings Panel.","Listing continues pending compliance; no immediate impact on trading."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226260,"accession_number":"0001493152-24-023860","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BriaPro subsidiary reports $317K net loss, $1 cash, going concern doubt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $316,517 for nine months ended April 30, 2024; zero revenue.","Cash and equivalents of $1; current liabilities $356,734; shareholders' deficit $301,924.","Going concern warning: dependent on future financing, significant doubt.","Intangible assets (patents) of $203,614 from August 2023 spin-out from BriaCell.","Operating loss of $366,960 for the nine-month period, R&D expense $227,249."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226259,"accession_number":"0001493152-24-020460","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"BriaCell raises $5.0M in registered direct offering with warrants; director participates","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $5.0M from sale of 2,402,935 shares (or pre-funded warrants) and warrants for additional 2,402,935 shares.","Combined purchase price: $2.00/share for institutional investors; $2.215/share for a director of the company.","Warrants exercisable at $2.11/share, beginning 6 months from issuance, expiring in 5 years.","Net proceeds to fund working capital and Phase 3 pivotal study in advanced breast cancer.","Closing occurred May 17, 2024; placement agent A.G.P./Alliance Global Partners received 7% fee and 50,000 warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226258,"accession_number":"0001493152-24-012774","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BriaPro subsidiary reports net loss of $246K; going concern doubt flagged","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BriaPro incurred net loss of $245,960 for six months ended Jan 31, 2024 (no prior-year comparison).","Assets of $207,432 (mainly intangible patents) offset by $250,678 current liabilities; shareholders' deficit of $231,367.","Going concern note: 'significant doubt' about ability to continue as pre-clinical stage company needs further financing.","Due to parent BriaCell $196,549 under transition services agreement; warrant liability of $188,121 recorded.","Operating loss of $257,057; R&D expenses $168,536 and G&A $88,494 for the six-month period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245315,"accession_number":"0001493152-24-004525","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2024-01-31T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BriaCell shareholders ratify MNP as auditor and re-elect all seven director nominees at AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ratified MNP LLP as independent auditor with 5,346,102 For, 0 Against, 28,968 Withheld.","Re-elected all seven directors: Gross, Lustig, Bondarenko, Williams, Taub, Embro-Pantalony, Schmieg.","Voter turnout: 5,375,071 common shares represented (33.6% of 15,981,726 outstanding shares) – quorum met."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262768,"accession_number":"0001493152-23-045569","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2023-12-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BriaCell reports prelim OS up to 2x literature in ADC-refractory breast cancer subset","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["23 heavily pre-treated (median 6 prior therapies) advanced breast cancer patients, all failed ADCs (KADCYLA, ENHERTU, TRODELVY).","Median OS up to twice that reported in comparable studies; 17 of 23 patients remain alive.","Disease control rate of 40% in evaluable patients; PFS similar or better than last regimen in 40%.","No toxicity-related discontinuations and no cases of Interstitial Lung Disease (ILD) with Bria-IMT regimen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262767,"accession_number":"0001493152-23-044891","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BriaCell's BriaPro subsidiary posts Q1 loss of $128K; holds $211K in intangible assets","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BriaPro completed spin-out from BriaCell on Aug 31, 2023, receiving Bria-TILsRx and PKCδ inhibitor assets.","Net loss of $128K for three months ended Oct 31, 2023; no revenue; operating loss $132K.","Intangible assets (patents) of $211K net; cash and equivalents of $1; accumulated deficit $148K.","Going concern uncertainty noted; BriaPro needs additional financing to continue operations.","BriaCell owns 2/3 of BriaPro; provides transition services for $20K/month."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262766,"accession_number":"0001493152-23-043142","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2023-11-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BriaCell reports new Phase 2 responder with 3-cycle orbital tumor resolution after 7 prior failed regimens","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Patient with proptosis from orbital metastatic breast cancer had remarkable improvement and pain reduction after 3 cycles of Bria-IMT combo.","Heavily pretreated patient had failed 7 prior regimens; continues treatment with well-tolerated regimen.","Second reported case of orbital tumor resolution; first patient had failed 12 regimens and 16 agents.","Additional Phase 2 survival updates and clinical data to be presented at San Antonio Breast Cancer Symposium Dec 6-7, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262765,"accession_number":"0001493152-23-039228","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2023-11-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BriaCell receives FDA clearance for Bria-OTS IND; reports preclinical data at SITC","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA authorized Bria-OTS IND for clinical study of off-the-shelf personalized breast cancer immunotherapy.","Preclinical data at SITC 2023 shows broad immune activation in tumor models by next-gen Bria-OTS+ and Bria-PROS+.","Data indicates personalized HLA-matched platform covers >99% of US population with favorable safety profile.","BriaCell expects to initiate clinical study of Bria-OTS and advance advanced versions for breast and prostate cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262764,"accession_number":"0001493152-23-038297","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2023-10-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BriaPro subsidiary files financials; spinout of cancer assets completed Aug 31, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BriaPro filed Jul 31, 2023 financials: $1 cash, zero revenue, inactive during period.","On Aug 31, 2023, BriaPro closed spinout of Bria-TILsRx and PKCδ inhibitors from parent BriaCell.","Spinout consideration: 47,945,178 BriaPro shares issued; BriaCell owns ~31,963,452 (2/3).","BriaCell options/warrants adjusted; 2,131,400 options and 8,121,650 warrants outstanding with split exercise prices.","BriaPro notes going concern uncertainty; will need additional financing to develop assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279946,"accession_number":"0001493152-23-032041","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2023-09-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BriaCell Phase 2 breast cancer study shows 13.5-month median overall survival vs 6.7-9.8 months literature","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median overall survival 13.5 months in BriaCell's Phase 2 study vs 6.7-9.8 months for similar advanced metastatic breast cancer patients in literature.","21 of 29 patients treated since 2022 remain alive, suggesting strong survival benefit with combination regimen.","No dose limiting toxicities reported; Phase 2 study fully enrolled with 46 heavily pre-treated patients (average 5 prior treatments).","Combination regimen of Bria-IMT™ with checkpoint inhibitors (pembrolizumab or retifanlimab-dlwr) shows tolerability and efficacy.","Data supports upcoming pivotal study in advanced breast cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279945,"accession_number":"0001493152-23-031982","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2023-09-07T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"BriaCell Therapeutics amends articles after share exchange under arrangement","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amended notice of articles and articles effective August 31, 2023.","All existing BriaCell common shares exchanged for new shares with identical rights.","Outstanding share count remains 15,981,726 following the exchange.","Shareholders retain one vote per share and dividend/liquidation rights unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279944,"accession_number":"0001493152-23-031359","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2023-08-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BriaCell closes spinout of BriaPro, distributes shares to existing shareholders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BriaCell completed spinout of BriaPro, receiving 2/3 ownership; shareholders get one BriaPro share and one new BriaCell share per old share.","BriaPro acquired pipeline assets Bria-TILsRx™ and PKCδ inhibitors for cancer indications.","New BriaCell common shares expected to begin trading on or about September 5, 2023 under symbol BCT.","BriaCell remains listed on Nasdaq and TSX; BriaPro is an unlisted reporting issuer in Canada.","Computershare will distribute certificates; letters of transmittal mailed to registered holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279943,"accession_number":"0001493152-23-031061","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2023-08-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BriaCell closes spinout of BriaPro to shareholders; retains 66.6% stake","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed plan of arrangement spinning out Bria-TILsRx™ and PKCδ inhibitors to BriaPro.","Shareholders receive one BriaPro share and one new BriaCell share per existing share.","BriaCell now owns ~66.6% (31,963,452 shares) of BriaPro's outstanding shares.","BriaPro becomes unlisted reporting issuer in Canada; BriaCell remains on Nasdaq and TSX.","New BriaCell common shares expected to trade on or about Sept 5, 2023 under 'BCT'."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279942,"accession_number":"0001493152-23-030245","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2023-08-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BriaCell gets court approval for spin-out of BriaPro Therapeutics, effective Aug 31, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Court approved spin-out of BriaPro Therapeutics with pipeline assets including Bria-TILsRx and PKCδ inhibitors.","Effective date expected August 31, 2023; SpinCo to be ~2/3 owned by BriaCell and ~1/3 by BriaCell shareholders.","Shareholders receive one SpinCo share and one new BriaCell share for each old share held.","BriaCell remains listed on Nasdaq and TSX; SpinCo to be unlisted reporting issuer in Canada."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279941,"accession_number":"0001493152-23-029604","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2023-08-21T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"BriaCell shareholders approve spinout of BriaPro Therapeutics with 98.9% support","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved Arrangement to spin out BriaPro Therapeutics (Bria-TILsRx, PKCδ inhibitors) with 98.92% votes.","SpinCo will be a 2/3 owned subsidiary of BriaCell; each share gets one SpinCo share and one new BriaCell share.","Closing expected on/around Aug 31, 2023, subject to final court approval on Aug 25 and regulatory approvals.","SpinCo Option Plan approved (89.70% votes); August 2022 option grant ratified (99.10% votes).","BriaCell remains listed on NASDAQ/TSX; SpinCo will become an unlisted reporting issuer in Canada."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298449,"accession_number":"0001493152-23-022575","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2023-06-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA approves BriaCell's registrational study design for Bria-IMT combo in advanced breast cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved primary and secondary endpoints, study design, and patient population for Bria-IMT plus checkpoint inhibitor in advanced metastatic breast cancer.","Trial is randomized, open-label with three arms: Bria-IMT combo, physician's choice, and Bria-IMT alone.","Patients must have exhausted all other treatment options; recruitment and dosing begin summer 2023.","Upon statistically significant milestones, BriaCell may apply for full approval via BLA filing.","CEO notes FDA's route to accelerate development for difficult-to-treat patient population."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298448,"accession_number":"0001493152-23-019652","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2023-05-31T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"BriaCell to spin out pre-clinical assets into BriaPro; shareholders get 1 SpinCo share per each held","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SpinCo to acquire Bria-TILsRx™ and PKCδ inhibitors from BriaCell.","Each BriaCell shareholder receives 1 SpinCo share and 1 new BriaCell share; warrants adjusted similarly.","Shareholders will own 33.33% of SpinCo; BriaCell retains 66.67%.","Special shareholder meeting scheduled for July 2023; closing targeted by August 2023.","Conditions: shareholder vote, court orders, TSX and Nasdaq approvals; board unanimously supports."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298447,"accession_number":"0001493152-23-018481","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"BriaCell closes $4M strategic investment by Prevail Partners at $8.63/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 463,408 common shares to Prevail Partners for aggregate gross proceeds of $4 million.","Price per share was US$8.63; TSX approved the transaction on May 18, 2023.","Proceeds to fund CRO clinical services and technologies for upcoming pivotal study in advanced metastatic breast cancer.","Shares subject to four-month-and-one-day hold period under Canadian securities laws.","Prevail Partners' affiliate, Prevail InfoWorks, will provide clinical services and real-time data analytics platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298446,"accession_number":"0001493152-23-017363","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"BriaCell signs $4M stock purchase and CRO agreement with Prevail for pivotal breast cancer study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Prevail InfoWorks to serve as CRO for BriaCell's pivotal advanced metastatic breast cancer study, expected in 2023.","BriaCell receives $4M from Prevail Partners for 463,408 shares at $8.63, a 20% premium to 30-day VWAP.","Upfront payment of $5,379,945 under MST Agreement, plus milestone fees; funds used to pay InfoWorks.","Stock purchase expected to close on or about May 19, 2023, subject to TSX approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298445,"accession_number":"0001493152-23-012566","cik":1610820,"company_name":"BriaCell Therapeutics Corp.","ticker":"BCTX","form_type":"8-K","filed_at":"2023-04-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BriaCell presents positive Bria-IMT data at AACR; 15/18 alive, immune activation in anergic patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["15 of 18 patients enrolled since 2021 remain alive; survival compares favorably to 6.7-9.8 months in similar studies.","PFS benefit: most patients had PFS similar or higher than prior therapy, suggesting better tolerability and clinical effectiveness.","Immune activation in 70% of anergic patients (weak immune systems) and 89% of non-anergic after Bria-IMT combo.","8 of 17 HR+ patients (large segment) experienced PFS benefit; no immunotherapies shown to work in HR+ breast cancer.","Next-gen Bria-OTS2.0 significantly more effective than Bria-OTS in activating naïve T-cells; planned for Phase I/IIa."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":34294803.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-04-17T23:59:59+00:00|298445"}